Does striatal volume contribute to the prediction of onset of Huntington disease in incident cases?
Results suggest that MRI volumetric measures may be helpful in selecting individuals for future clinical trials in pre-HD where HD motor onset is the primary outcome measure. In planning for multisite clinical trials in pre-HD, investigators may also want to consider using more objective measures, such as MRI volumes, in addition to onset of diagnosable movement disorder, as major outcome measures.
The algorithm reliably allocates individuals into acquisition precontemplation, but for all other stages, its reliability is fair.